Balcom Alexandra 4

What Happened

• Alexandra Balcom, a director of Crescent BioPharma (CBIO), was granted a derivative award on 2026-06-02 representing the right to purchase 11,050 ordinary shares. The Form 4 reports the acquisition at $0.00 (no cash paid at grant); this is an option/award, not an immediate share purchase or sale.

Key Details

• Transaction date: June 2, 2026; Form filed June 3, 2026 (appears timely).
• Reported transaction type/code: A (award/grant); derivative security (option) for 11,050 shares.
• Amount paid at grant: $0.00 (the filing shows no cash exchanged); the option’s exercise/strike price is not stated in the provided excerpt.
• Vesting: Vests in full on the earlier of (i) June 2, 2027 or (ii) the issuer’s next annual meeting of shareholders, subject to Balcom’s continued service (per footnote F1).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• No indication of a 10b5-1 plan, tax withholding, or late filing in the materials provided.

Context

• This was an option grant (a right to buy shares later if conditions are met), not an exercise or sale — no shares were issued or sold immediately. Such awards are commonly used as director compensation and vest over time subject to continued service; they do not, by themselves, indicate immediate buying or selling intent.